5 Key Takeaways

• 1

  Genetically engineered CAR T cells can evade tumor immune suppression, potentially extending therapies to solid cancers.

• 2

  Disabling EP2 and EP4 receptors in CAR T cells allows them to remain active in PGE2-rich tumor environments.

• 3

  The modified CAR T cells showed improved tumor control in mouse models of pancreatic cancer, melanoma, and mesothelioma.

• 4

  The enhanced persistence of EP2/EP4-deficient CAR T cells, rather than increased killing capacity, contributes to better outcomes.

• 5

  The researchers plan to test this strategy in clinical studies, starting with lymphoma before moving to solid tumors.